Are Biotech Startups Ready for Augmented Reality?
Augmented reality is starting to become a part of the manufacturing process of pharma and biotech companies. Paul Haimes, Vice President of Engineering at PTC, discusses the benefits and challenges to implementing this technology across the biotech industry.
Augmented reality (AR) is increasingly being used to maintain and optimize biomanufacturing processes, which can bring economic benefits for biotech and pharma companies long term. In addition, the technology can provide remote work and knowledge-sharing options, which have proven particularly relevant in pandemic times. However, especially for small to medium-sized life science companies, a better understanding of the technology’s benefits and how to apply it is still lacking.
“You need to examine: how does it save you money or make you money; does it increase sales; does it create a better working environment; will it solve a production bottleneck? These scenarios must be explored before you press the button on AR,” says Paul Haimes.
Paul Haimes is the Vice President of Engineering for PTC, a company that develops digital solutions for manufacturing, in Europe, the Middle East, and Africa. With over 20 years of product development experience, one of his areas of expertise covers smart connected products, the internet of things, and AR.
Why aren’t we seeing more small biotech companies embrace AR? Is this mainly due to high costs of entry?
It’s not the high cost of entry, as hardware and software are now within the reach of small- to medium-sized businesses. There is, however, a lack of understanding of the use cases and what value they may actually bring.
Please, to access the full article visit Labiotech